Financial Review: Peak Pharmaceuticals (OTCMKTS:PKPH) versus Inventiva (NASDAQ:IVA)

Peak Pharmaceuticals (OTCMKTS:PKPH) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Risk & Volatility

Peak Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Profitability

This table compares Peak Pharmaceuticals and Inventiva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Pharmaceuticals	N/A	N/A	-159.55%
Inventiva	N/A	N/A	N/A

Insider and Institutional Ownership

19.1% of Inventiva shares are held by institutional investors. 18.4% of Peak Pharmaceuticals shares are held by company insiders. Comparatively, 32.0% of Inventiva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Peak Pharmaceuticals and Inventiva’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Peak Pharmaceuticals	N/A	N/A	-$160,000.00	N/A	N/A
Inventiva	$17.48 million	6.76	-$119.51 million	N/A	N/A

Peak Pharmaceuticals has higher earnings, but lower revenue than Inventiva.

Analyst Ratings

This is a summary of current ratings and price targets for Peak Pharmaceuticals and Inventiva, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Peak Pharmaceuticals	0	0	0	0	N/A
Inventiva	0	0	7	0	3.00

Inventiva has a consensus price target of $17.00, indicating a potential upside of 655.56%. Given Inventiva’s higher probable upside, analysts plainly believe Inventiva is more favorable than Peak Pharmaceuticals.

Summary

Inventiva beats Peak Pharmaceuticals on 7 of the 8 factors compared between the two stocks.

About Peak Pharmaceuticals

Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ.

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.